Replies to post #612343 on NorthWest Biotherapeutics Inc (NWBO)

[supersteve13]

There are institutions invested here- even more lies from PoorMan! :)

I certainly don’t think everyone is lying- but it’s fact that you are. :)

[CrashOverride]

Says the ketamine klutz who claims to be long but wants the company sold for pennies on the dollar. Clearly meshuggeneh!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172389259

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172398256

[ATLnsider]

Poor Man, are you saying that after NWBio accomplishes all of the major milestones on my list below, all NWBO shares, and including the DCVax dendritic cell vaccine platform, for all or most solid tumor cancers, both operable and inoperable, will only be worth $15 billion?

(1) DCVax-L is approved initially in the US, UK, Canada, Germany and the rest of the EU.

(2) DCVax-L is approved in most of the rest of the world.

(3) DCVax-L is eventually approved as a tissue agnostic treatment for all or most solid tumor cancers. I gradually increased annual global patients each year.

(4) The average revenue per patient for DCVax-L starts out initially at $150,000 per patient. Then because of manufacturing efficiencies due to using Flaskworks devices, and economies of scale due to an increasing number of customers treated each year, the revenue per patient would gradually decrease by about 50%, from $150,000 down to $75,000.

(5) The average multiple of price to sales for a biotech drug company is 5.78. I used this multiple to calculate the total valuation of NWBio for each level of customers treated:

https://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/psdata.html

(6) The value per share is initially based on 1.5 billion shares outstanding. I increased the number of outstanding shares to 1.6 billion shares after the annual number of cancer patients treated exceeded 10,000 patients per year.

Here are the results of these projections below. You can see an eventual valuation of over $1.73 trillion, which equates to $1,083.75 per share, based on 1.6 billion NWBO shares outstanding